UCB's Global Corporate Website
Welcome to UCB in the United States

U.S. Public Policy Inspired by Patients: Value-Based Care


UCB is committed to delivering value-based care for patients through policy approaches that:

Remove policy barriers to collaboration among patients, payers, providers, caregivers, and policymakers in developing value- and outcomes-based payment models

  • We support creating an environment more conducive to value-based care, including by allowing new flexibilities or exemptions from current regulatory barriers such as Medicaid Best Price and the Anti-Kickback Statute.
  • We support the continued ability for public and commercial payers to evolve from “one-size-fits-all” formulary designs to value-based insurance design models that improve patient access to the right medicine at the right time.

Support informed, shared healthcare decision-making between patients and physicians

  • We support regulatory processes that enable sharing of balanced, straightforward, evidence-based information about medicines that enable patients and providers to make informed healthcare decisions.
  • We support patient empowerment through ready access to meaningful and understandable data on their condition and treatment options.

Promote an environment that rewards value and encourages continued medical innovation

  • We support evolving the healthcare ecosystem by removing barriers to private market solutions that foster continued innovation, protect patient access, and promote the development of new life-changing medicines.
  • We oppose inhibiting competition, innovation, and sustainable value creation, including arbitrary government price-setting, pricing based on foreign markets, or proposals that require the disclosure of proprietary information.

Incorporate the patient voice and real-world evidence (RWE)5 in healthcare quality measures and value assessments

  • We support integrating the patient voice, patient-reported outcomes, and RWE into value assessment frameworks and quality measurement.
  • We support increased recognition of the differentiated value of medicines that modify or cure underlying disease.
  • We strongly oppose quality measures or value assessment frameworks that diminish or discount the value of human life based on age, gender, disability or other factors.

Foster a value assessment environment that recognizes multiple frameworks and definitions of value

  • We support the development and use of multiple value assessment frameworks and the recognition of a variety of definitions of what constitutes value to patients, providers, payers, caregivers, and society.


UCB recognizes our obligation to our patients, the healthcare ecosystem, and society, and is committed to driving sustainable solutions that deliver value-based care for patients by:

  • Collaborating with patient organizations to identify and incorporate the outcomes of greatest significance to patients into value assessment frameworks, with specific effort to include subpopulations with unique unmet needs.
  •  Partnering with public and commercial payers on value- and outcomes-based pricing and contracting models for our medicines.
  • Investing in the continued development of evidence that demonstrates the value of our medicines to the Food and Drug Administration (FDA), the Centers for Medicare and Medicaid (CMS), private payers, providers, and, most importantly, patients.
  • Working to improve the sustainability of our company, the overall healthcare ecosystem, and the environment.


UCB considers RWE to be any clinical and/or economic findings with respect to disease burden, treatment utilization and outcomes, comparative effectiveness, etc. that analyzes real-world data. Real-world data includes, but is not limited to, medical and pharmacy administrative claims, electronic medical/health records, product/disease registries, and patient-reported outcomes collected through various channels. Methods and analytical approaches (including artificial intelligence) to real-world data collection and RWE generation can vary, but acknowledge that RWE must be appropriately executed based on proposed research objectives and be fit for purpose.